F104S c-Mpl responds to a transmembrane domain−binding thrombopoietin receptor agonist: Proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents
Experimental Hematology2010Vol. 38(5), pp. 384–391
Citations Over Time
Related Papers
- → A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival(2012)31 cited
- → Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor(2007)27 cited
- → Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide.(1988)104 cited
- → PCR246 Patient Preferences Regarding Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia in Italy (TRAPeze Italy Study)(2022)2 cited
- → Megakaryocytes Do Not Express Erythropoietin Receptor (EpoR) and Do Not Respond to Recombinant Human Erythropoietin (rHuEpo) Stimulation(2011)